Your 50s, evidence first.

Kang 2005 ran a 2-year randomized, placebo-controlled trial of 0.05% tretinoin emollient cream in 204 adults with moderate-to-severe photodamage: significant improvement in photoaging scores with increased procollagen on histology after long-term use. Systematic reviews and a meta-analysis of the tretinoin RCTs (participants mostly 40–70) confirm consistent improvement in fine wrinkling, mottled pigment and roughness, with retinoid dermatitis the main cost and the 0.02–0.05% strengths delivering most of the benefit. Retinol products approach tretinoin in split-face comparisons but are less potent per unit.

Postmenopausal skin is drier and more reactive: 0.025% two or three nights a week over a ceramide moisturizer, building up over months; expect 6–12 months for wrinkle change. Neck and hands included.

Daily sunscreen is the intervention with the clearest evidence for both slower photoaging and fewer keratinocyte cancers and melanomas, principally from the Australian Nambour randomized trial and its long-term follow-up. In the 50s the case strengthens: melanoma incidence keeps rising with age, and every pigment or resurfacing treatment below recurs or complicates without photoprotection. SPF 50, mineral if reactive, reapplied when outdoors.

Female pattern hair loss accelerates after menopause. Lucky 2004 found topical 5% minoxidil beat 2% and placebo on hair counts and patient ratings; a 24-week RCT found oral 1 mg comparable to topical 5% with more facial hair (27% vs 4%); and a 2022 evaluator-blinded RCT found adding spironolactone or microneedling to minoxidil improved outcomes. The mechanism is androgen-independent, so extrapolation to 50–59 is reasonable; expect thickening rather than restoration, and commit for six months before judging.

The Manchester lipid study makes ceramide moisturizers a rational default: postmenopausal stratum corneum has lower ceramide abundance and shorter chains — a leakier barrier — with serum estradiol tracking ceramide levels. A randomized trial of a pseudo-ceramide cream showed absorption into the stratum corneum with reduced water loss and an improved ceramide profile. Expect comfort, tolerance for your retinoid, and glow — no wrinkle outcomes (full grading in our ceramides guide).

Topical L-ascorbic acid (10–20%) and niacinamide (2–5%) each have small vehicle-controlled trials showing modest improvement in fine lines and pigmentation over 8–12 weeks — niacinamide's best trial was run in women aged 40–60. Useful under sunscreen and alongside a retinoid; not pillars. Peptides and growth-factor serums, by contrast, rest mostly on open-label industry studies.

Lentigines and seborrhoeic keratoses multiply after 50. A 2025 systematic review of 41 trials (3,234 patients, ages 24–92) ranks the options: IPL 75–90% good-to-excellent clearance, picosecond lasers 68–93%, Q-switched 36–77%, topical mequinol/tretinoin 53–80%, cryotherapy 37–71% with the most side effects, TCA peels 12–46%. Hydroquinone remains the reference lightener for melasma-type pigment but is prescription-only in the EU/UK and weaker than a laser for discrete spots; oral tranexamic acid's evidence is in melasma and carries clotting exclusions. For sun spots, light beats cream.

Schmidt 1996 applied estradiol or estriol cream to the face of 59 peri- and postmenopausal women for six months and reported better elasticity, reduced wrinkle depth and pore size, and more type III collagen on biopsy — without a placebo arm. A 2025 JAAD Reviews article concludes the evidence is promising but small, uncontrolled or short, with unresolved questions about systemic absorption and long-term breast and endometrial safety. No estrogen facial cream is approved in the EU or UK; estriol creams are compounded, off-label prescriptions. Interesting, unproven, and a conversation for a menopause specialist rather than a clinic counter.

The "menopause skincare" shelf sells peptides, growth factors and botanical "phytoestrogens" on mechanism and open-label data; none has a controlled trial with clinical endpoints in postmenopausal skin. What the shelf gets right is the problem — dryness, thinning, dullness — and what solves it is graded above: barrier lipids, a retinoid, sunscreen, and (if indicated for other reasons) systemic hormone therapy. Pay for the actives with trials.

The 2022 Menopause Society position statement: hormone therapy is the most effective treatment for vasomotor symptoms and genitourinary syndrome and prevents bone loss and fracture; for symptomatic women under 60 or within 10 years of menopause without contraindications, benefits generally outweigh risks, and starting later carries a less favourable ratio. The 2024 JAMA review of the WHI trials reiterates the early-menopause advantage and individualized decisions; in WHI, estrogen-plus-medroxyprogesterone carried a small absolute breast-cancer increase while estrogen alone did not — and modern European regimens are pharmacologically different. Everyone in the 50s is at or near the window's edge; the consultation belongs early in the decade.

Two formulation choices carry most of the safety difference. Route: the ESTHER and E3N studies found oral, but not transdermal, estrogen raised venous thromboembolism risk; a US claims analysis and ACOG agree, endorsing transdermal routes for higher-risk women. Progestogen: in E3N (78,353 women), estrogen with micronized progesterone or dydrogesterone was not associated with increased breast-cancer risk for up to about five years, and micronized progesterone was not associated with clots. These regulated products are themselves "body-identical" — the distinction that matters is regulated versus compounded.

The trial that overturned "don't lift heavy": LIFTMOR randomized 101 postmenopausal women with low bone mass to eight months of supervised high-intensity resistance and impact training (5×5 at over 85% of max — deadlift, squat, overhead press, plus jumping chin-ups) or a home low-intensity programme. Lumbar-spine density improved about four percentage points relative to control, with better femoral-neck outcomes, stronger back extensors, taller stature and faster timed up-and-go — and a single minor adverse event. A 2025 review summarizes the follow-on trials. Creatine at 5 g/day adds small lean-mass and strength gains with training in postmenopausal meta-analysis; it does not raise bone density on its own.

USPSTF 2025 (Grade B): screen all women at 65, and younger postmenopausal women at increased risk — low weight, parental hip fracture, smoking, alcohol, early menopause, glucocorticoids. Given SWAN's curve, a baseline scan around the final period is reasonable with any risk factor. Vitamin D and calcium have no fracture benefit in non-deficient community-dwelling women: correct deficiency, don't megadose. Hormone therapy is the most effective bone-preserving agent in early postmenopause; heavy training (above) is the one with the RCT you can join at a gym.

SWAN shows LDL cholesterol rising across the transition attributable to menopause rather than age, on top of visceral-fat gain; a 2025 review covers sex-specific lipid metabolism. The rational panel: full lipids with ApoB annually, Lp(a) once (genetically fixed), HbA1c, waist circumference and blood pressure — and a coronary-artery-calcium score for intermediate risk in the late 50s to settle the statin question. Cardiorespiratory fitness and alcohol reduction carry the strongest mortality associations of anything on this page (our longevity-clinic guide grades the tests).

Sixty postmenopausal nuns randomized to a year of oral estrogen or placebo grew dermis about 30% thicker on thigh biopsy (Maheux 1994, described in "Estrogens and aging skin"); Brincat's cohorts showed women on replacement did not lose collagen the way untreated women did. The Menopause Society rates skin thickness, elasticity and collagen benefits as Level II evidence when HT is given at menopause. Against that: Phillips 2008, the largest trial to measure the face, found no meaningful wrinkle benefit over placebo, and no guideline recommends HT for skin. The honest reading: it preserves; it does not reverse; take it for the right reasons and count the skin as a bonus.

A systematic review of "Ozempic face" finds the phenomenon real but descriptive: rapid large weight loss deflates the structural deep fat compartments and exposes skin laxity — temples, cheeks and tear troughs most visibly — and in women over 50 it stacks on the baseline losses above. Proposed direct drug effects on fibroblasts are hypotheses. The practical advice is robust: lose slowly, resistance-train and hit protein during loss, and defer any structural filler until weight has been stable for six months.

The 2020 National Academies report found insufficient evidence of safety or effectiveness to justify compounded bioidentical hormone therapy except for documented allergy or dose needs; the Endocrine Society highlights supraphysiological blood levels and endometrial-cancer reports with pellets; ACOG says compounded therapy should not be prescribed routinely. Regulated transdermal estradiol and micronized progesterone are already body-identical — the marketing distinction is a false one.

The 2019 Global Consensus Position Statement — endorsed by the International Menopause Society, the Endocrine Society and others — concludes that the only evidence-based indication for testosterone in women is hypoactive sexual desire disorder after menopause, with a moderate effect, at doses keeping levels in the female physiological range. There is no evidence supporting it for skin, body composition, bone, mood or cognition — precisely the menu "vitality" clinics sell it for.